ADC Therapeutics SA (ADCT) Tops Q2 EPS by 12c

ADC Therapeutics SA (NYSE: ADCT) reported Q2 EPS of ($0.58), $0.12 better than the analyst estimate of ($0.70). Revenue for the quarter came in at $19.2 million versus the consensus estimate of $20.25 million.

For earnings history and earnings-related data on ADC Therapeutics SA (ADCT) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• zSpace, Inc. (ZSPC) Reports Q2 results
• Kodiak Sciences Inc. (KOD) Misses Q2 EPS by 7c